KRAS and colorectal carcinoma: Our analysis revealed that KRAS Q61 and NRAS mutations have distinct clinical-pathological features, and KRAS G12/G13 mutation with different AFs was ubiquitous in this cohort, probably being essential for the CRC initiation and development.